[{"address1": "10 Earlsfort Terrace", "city": "Dublin", "zip": "2", "country": "Ireland", "phone": "353 1 901 5201", "website": "https://www.avadel.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.", "fullTimeEmployees": 154, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gregory J. Divis Jr.", "age": 57, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 985200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas S. McHugh", "age": 59, "title": "Senior VP, Principal Financial and Accounting Officer & CFO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 663144, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jerad G. Seurer", "age": 51, "title": "General Counsel & Company Secretary", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory J. Davis", "age": 59, "title": "VP of Corporate and Business Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark W. Elrod", "title": "Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angie  Woods", "title": "Vice President of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jordan S. Dubow M.D.", "age": 46, "title": "Consultant", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 727933, "exercisedValue": 395250, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jason M. Vaughn", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Gudeman PharmD", "title": "Senior Vice President of Medical & Clinical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 5, "shareHolderRightsRisk": 3, "overallRisk": 4, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.99, "open": 8.99, "dayLow": 8.6, "dayHigh": 9.08, "regularMarketPreviousClose": 8.99, "regularMarketOpen": 8.99, "regularMarketDayLow": 8.6, "regularMarketDayHigh": 9.08, "forwardPE": 67.800606, "volume": 894840, "regularMarketVolume": 894840, "averageVolume": 1406127, "averageVolume10days": 1489910, "averageDailyVolume10Day": 1489910, "bid": 8.6, "ask": 11.05, "bidSize": 1200, "askSize": 200, "marketCap": 829672512, "fiftyTwoWeekLow": 7.39, "fiftyTwoWeekHigh": 19.09, "priceToSalesTrailing12Months": 6.005157, "fiftyDayAverage": 9.3296, "twoHundredDayAverage": 13.43255, "currency": "USD", "enterpriseValue": 802119744, "profitMargins": -0.52529997, "floatShares": 84737437, "sharesOutstanding": 96361504, "sharesShort": 10552970, "sharesShortPriorMonth": 11770961, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1095, "heldPercentInsiders": 0.04776, "heldPercentInstitutions": 0.85382, "shortRatio": 6.09, "shortPercentOfFloat": 0.1252, "impliedSharesOutstanding": 96361504, "bookValue": 0.775, "priceToBook": 11.109677, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -72575000, "trailingEps": -0.75, "forwardEps": 0.68, "enterpriseToRevenue": 5.806, "enterpriseToEbitda": -12.936, "52WeekChange": -0.30093312, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AVDL", "underlyingSymbol": "AVDL", "shortName": "Avadel Pharmaceuticals plc", "longName": "Avadel Pharmaceuticals plc", "firstTradeDateEpochUtc": 834154200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "eed4625d-e4bb-3438-b887-c6091808e157", "messageBoardId": "finmb_28567", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.61, "targetHighPrice": 22.0, "targetLowPrice": 12.0, "targetMeanPrice": 17.6, "targetMedianPrice": 18.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 65807000, "totalCashPerShare": 0.683, "ebitda": -62007000, "totalDebt": 38254000, "quickRatio": 2.405, "currentRatio": 2.974, "totalRevenue": 138160000, "debtToEquity": 51.236, "revenuePerShare": 1.477, "returnOnAssets": -0.2214, "returnOnEquity": -0.78539, "grossProfits": 127002000, "freeCashflow": -58922500, "operatingCashflow": -82809000, "revenueGrowth": 6.132, "grossMargins": 0.91924006, "ebitdaMargins": -0.44881, "operatingMargins": -0.00654, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]